Pharmacological strategies for self-management of asthma exacerbations

European Respiratory Journal

Volumn 28, Issue 1, 2006, Pages 182-199

  Reddel, H K ^a   Barnes, D J ^b  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Asthma exacerbations; Asthma management; Asthma pharmacotherapy; Combined modality therapy; Self management

Indexed keywords

AMINOPHYLLINE; AMOXICILLIN; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DD SERETIDE ACCUHALER; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HYDROCORTISONE; LEVALBUTEROL; LONG ACTING DRUG; MAGNESIUM; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE;

ADRENAL INSUFFICIENCY; ANXIETY DISORDER; ASTHMA; BRONCHODILATATION; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HOARSENESS; HUMAN; INSOMNIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MOOD DISORDER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SELF MEDICATION; SINGLE DRUG DOSE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; COMBINED MODALITY THERAPY; HUMANS; SELF CARE;

EID: 33845495413     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00105305     Document Type: Review

References (94)

1. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071-1076.
2. Reddel H, Ware S, Marks G, et al. Differences between asthma exacerbations and poor asthma control [erratum in Lancet 1999;353:758]. Lancet 1999; 353: 364-369.
3. Janson S, Becker G. Reasons for delay in seeking treatment for acute asthma: the patient's perspective. J Asthma 1998; 35: 427-435.
4. Rea HH, Sears MR, Beaglehole R, et al. Lessons from the national asthma mortality study: circumstances surrounding death. N Z Med J 1987; 100: 10-13.
5. Gibson PG, Powell H, Coughlan J, et al., Self-management education and regular practitioner review for adults with asthma (Cochrane review). 2003; Oxford, Update Software, The Cochrane Library, Issue 1.
6. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004; 59: 94-99.
7. Harrison TW, Oborne J, Newton S, et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271-275.
8. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
9. Hasegawa T, Ishihara K, Takakura S, et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Intern Med 2000; 39: 794-797.
10. Jones AM, Munavvar M, Vail A, et al. Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med 2002; 96: 950-954.
11. O'Driscoll BR, Kalra S, Wilson M, et al. Double-blind trial of steroid tapering in acute asthma. Lancet 1993; 341: 324-327.
12. Hatton MQ, Vathenen AS, Allen MJ, et al. A comparison of "abruptly stopping" with "tailing off" oral corticosteroids in acute asthma. Respir Med 1995; 89: 101-104.
13. Cydulka RK, Emerman CL. A pilot study of steroid therapy after emergency department treatment of acute asthma: is a taper needed? J Emerg Med 1998; 16: 15-19.
14. Karan RS, Pandhi P, Behera D, et al. A comparison of non-tapering vs. tapering prednisolone in acute exacerbation of asthma involving use of the low-dose ACTH test. Int J Clin Pharmacol Ther 2002; 40: 256-262.
15. FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-556.
16. Rice-McDonald G, Bowler S, Staines G, et al. Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Intern Med J 2005; 35: 693-698.
17. Foresi A, Morelli MC, Catena E, et al. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000; 117: 440-446.
18. Levy ML, Stevenson C, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 1996; 51: 1087-1092.
19. Nana A, Youngchaiyud P, Charoenratanakul S, et al. High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J Asthma 1998; 35: 647-655.
20. FitzGerald JM, Shragge D, Haddon J, et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J 2000; 7: 61-67.
21. Lee-Wong M, Dayrit FM, Kohli AR, et al. Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. Chest 2002; 122: 1208-1213.
22. Di Franco A, Bacci E, Bartoli ML, et al. Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization. Pulm Pharmacol Ther 2006; (In press).
23. Guttman A, Afilalo M, Colacone A, et al. The effects of combined intravenous and inhaled steroids (beclomethasone dipropionate) for the emergency treatment of acute asthma. The Asthma ED Study Group. Acad Emerg Med 1997; 4: 100-106.
24. Afilalo M, Guttman A, Colacone A, et al. Efficacy of inhaled steroids (beclomethasone dipropionate) for treatment of mild to moderately severe asthma in the emergency department: a randomized clinical trial. Ann Emerg Med 1999; 33: 304-309.
25. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med 1998; 157: 698-703.
26. Pansegrouw DF. Acute resistant asthma caused by excessive beta-2-adrenoceptor agonist inhalation and reversed by inhalation of beclomethasone. S Afr Med J 1992; 82: 179-182.
27. Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med 2005; 171: 1231-1236.
28. Leuppi JD, Downie SR, Salome CM, et al. A single high dose of inhaled corticosteroids: a possible treatment of asthma exacerbations. Swiss Med Wkly 2002; 132: 7-11.
29. Canonica GW, Castellani P, Cazzola M, et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm Pharmacol Ther 2004; 17: 239-247.
30. Ind PW, Haughney J, Price D, et al. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med 2004; 98: 464-475.
31. Leuppi JD, Salzberg M, Meyer L, et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Med Wkly 2003; 133: 302-309.
32. Buhl R, Kardos P, Richter K, et al. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Curr Med Res Opin 2004; 20: 1209-1220.
33. Stallberg B, Olsson P, Jorgensen LA, et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003; 57: 656-661.
34. FitzGerald JM, Sears MR, Boulet LP, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003; 10: 427-434.
35. Balanag VM, Yunus F, Yang P-C, et al. Efficacy and safety of budesonide/ formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 2005; 19: 139-147.
36. Turner MO, Johnston PR, Pizzichini E, et al. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J 1998; 5: 261-268.
37. Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 2003; 97: 1067-1074.
38. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 2001; 163: 32-36.
39. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-1418.
40. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136.
41. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005; 60: 740-746.
42. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161: 1862-1868.
43. in't Veen JC, Smits HH, Hiemstra PS, et al. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 1999; 160: 93-99.
44. Gibson PG, Wong BJO, Hepperle MJE, et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992; 22: 525-532.
45. Wark PA, Johnston SL, Moric I, et al. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J 2002; 19: 68-75.
46. Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353: 2213-2214.
47. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875-879.
48. Aalbers R, Backer V, Kava TT, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20: 225-240.
49. FitzGerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005; 27: 393-406.
50. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crif Care Med 2004; 170: 836-844.
51. Rowe BH, Keller JL, Oxman AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analysis. Am J Emerg Med 1992; 10: 301-310.
52. Rowe BH, Spooner CH, Ducharme FM, et al. Corticosteroids for preventing relapse following acute exacerbations of asthma. [Update of Cochrane Database Syst Rev 2000;(2):CD000195; PMID: 10796506]. Cochrane Database of Systematic Reviews 2001: CD000195.
53. Edmonds ML, Camargo CA Jr, Brenner BE, et al. Replacement of oral corticosteroids with inhaled corticosteroids in the treatment of acute asthma following emergency department discharge: a meta-analysis. Chest 2002; 121: 1798-1805.
54. Edmonds ML, Camargo CA Jr, Pollack CV Jr, et al. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. [Update of Cochrane Database Syst Rev. 2001;(1):CD002308; PMID: 11279763]. Cochrane Database of Systematic Reviews 2003: CD002308.
55. Adolffson LE, Lundgren M, Tilling B, et al. Short-term safety and tolerability of double-dose salmeterol/fluticasone propionate in adult asthmatic patients. Clin Drug Invest 2005; 25: 231-241.
56. Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma. Cochrane Database of Systematic Reviews 2000: CD002742.
57. Rowe BH, Bretzlaff JA, Bourdon C, et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews 2000: CD001490.
58. Blitz M, Blitz S, Hughes R, et al. Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest 2005; 128: 337-344.
59. Travers A, Jones AP, Kelly K, et al. Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database of Systematic Reviews 2001: CD002988.
60. Cates CC, Bara A, Crilly JA, et al. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database of Systematic Reviews 2003: CD000052.
61. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102: 943-952.
62. Lotvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108: 726-731.
63. Hardasmalani MD, DeBari V, Bithoney WG, et al. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21: 415-419.
64. Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute paediatric asthma. Ann Emerg Med 2005; 46: 29-36.
65. Ralston ME, Euwema MS, Knecht KR, et al. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute paediatric asthma: a randomized controlled trial. J Emerg Med 2005; 29: 29-35.
66. Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J 1999; 14: 283-287.
67. Cockcroft DW, Davis BE, Swystun VA, et al. Tolerance to the bronchoprotective effect of beta2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol 1999; 103: 1049-1053.
68. Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001; 108: 681-684.
69. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-206.
70. Tan KS, Grove A, McLean A, et al. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997; 156: 28-35.
71. Aziz I, Lipworth BJ. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. Chest 1999; 115: 623-628.
72. Lipworth BJ, Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol 1999; 103: 88-92.
73. Jones SL, Cowan JO, Flannery EM, et al. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J 2001; 17: 368-373.
74. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; 117: 156-162.
75. Hancox R, Haney S. Tolerance to beta-agonist bronchodilation is not overcome by high dose salbutamol. Respirology 2004; 9: A31.
76. Boulet LP, Cartier A, Milot J, et al. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur Respir J 1998; 11: 1091-1097.
77. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med 1996; 154: 1603-1607.
78. Kalra S, Swystun VA, Bhagat R, et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-956.
79. Korosec M, Novak RD, Myers E, et al. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 1999; 107: 209-213.
80. Nakano Y, Enomoto N, Kawamoto A, et al. Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. J Allergy Clin Immunol 2000; 106: 472-478.
81. Graham V, Lasserson T, Rowe BH. Antibiotics for acute asthma. Cochrane Database of Systematic Reviews 2001: CD002741.
82. Graham VA, Milton AF, Knowles GK, et al. Routine antibiotics in hospital management of acute asthma. Lancet 1982; 1: 418-420.
83. Guittet L, Blaisdell CJ, Just J, et al. Management of acute asthma exacerbations by general practitioners: a cross-sectional observational survey. Br J Gen Pract 2004; 54: 759-764.
84. Lantner R, Brennan RA, Gray L, et al. Inpatient management of asthma in the Chicago suburbs: the Suburban Asthma Management Initiative (SAMI). J Asthma 2005; 42: 55-63.
85. Johnson SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006; 354: 1589-1600.
86. Edwards MR, Kebadze T, Johnson MW, et al. New treatment regimes for virus-induced exacerbations of asthma. Pulm Pharmacol Ther 2006; (In press).
87. Pizzichini MMM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997; 155: 1501-1508.
88. Fahy JV, Kim KW, Liu J, et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995; 95: 843-852.
89. Grissell TV, Powell H, Shafren DR, et al. Interleukin-10 gene expression in acute virus-induced asthma. Am J Respir Crit Care Med 2005; 172: 433-439.
90. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163: 406-412.
91. de Gouw HW, Grunberg K, Schot R, et al. Relationship between exhaled nitric oxide and airway hyperresponsiveness following experimental rhinovirus infection in asthmatic subjects. Eur Respir J 1998; 11: 126-132.
92. National Asthma Education and Prevention Program Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. NIH Publication 97-4051, 1997.
93. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58: i1-i94.
94. GINA (Global Initiative for Asthma). Workshop Report. Global strategy for asthma management and prevention. NIH. www.ginasthma.com. Date last accessed: January 2006.